Bharat Biotech and Precisa Medicamentos have inked a deal on supplies of Covaxin. The first consignment of vaccine is likely to be shipped shortly.
According to a press brief released by Bharat Biotech on Jan 12, 2021, the decision came after a team from the Brazilian company visited the Bharath Biotech facility at Genome Valley, Hyderabad, and discussed the potential export possibility of Covaxin after meeting Dr. Krishna Ella, the Chairman and Managing Director of Bharath Biotech on Jan.7 and 8. The discussion was joined virtually by André Aranha Corrêa do Lago, the Brazilian Ambassador to India.
Dr. Ella released a statement saying that she was pleased with the Brazilian government's interest in Covaxin. Her company aims to “serve the health of the people around the world” from the pandemic and that they have “always developed vaccines for a global cause.”
According to A Hindu report, Bharat Biotech is likely to supply twelve million doses of Covaxin to Brazil, and the first consignment would be shipped very soon.
The report also quoted the World Health Organisation (WHO) data and said that Brazil has reported over eight million COVID-19 cases and 203,100 deaths so far.
The approval comes as India has only approved the emergency use of Covaxin, and the health experts and opposition lawmakers have criticized its approval due to a lack of efficacy data, which the manufacturer is still conducting.
According to Reuters, the vaccine is still undergoing its phase-3 trials in 26,000 volunteers across the country, which began mid-Nov 2020.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.